Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr18.70 SEK
Change Today -0.30 / -1.58%
Volume 7.9K
BIOT On Other Exchanges
BIOT is not on other exchanges.
As of 11:29 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

biotage ab (BIOT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - kr19.30
52 Week Low
08/7/14 - kr9.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOTAGE AB (BIOT)

Related News

No related news articles were found.

biotage ab (BIOT) Related Businessweek News

No Related Businessweek News Found

biotage ab (BIOT) Details

Biotage AB (publ) provides solutions, knowledge, and experience in the areas of analytical chemistry, medicinal chemistry, peptide synthesis, separation, and purification in the United States, Europe, and Japan. The company offers systems and related consumables for evaporation, flash purification, microwave synthesis, peptide synthesis and purification, sample preparation, work-up tools, and process development solutions in organic chemistry and analytical chemistry areas. It also offers contract-research services, as well as develops and produces polymer based materials. The company sells its products to pharmaceutical and biotech companies, contract research organizations and contract manufacturing organizations, and academic institutions. Biotage AB (publ) is headquartered in Uppsala, Sweden.

284 Employees
Last Reported Date: 04/28/15

biotage ab (BIOT) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.0M
Compensation as of Fiscal Year 2014.

biotage ab (BIOT) Key Developments

Scientific Plastic Products, Inc. Files Lawsuit Against Biotage for Patent Infringement

A lawsuit was filed against Biotage by Scientific Plastic Products Inc. concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and 7,410,571. Biotage then filed requests with the US Patent and Trademark Office for reexamination of all patent claims in the Patents. At the same time Biotage moved to stay the lawsuit in the district court pending the outcome of the re-examination proceedings with the consent of SPP, and the court stayed the district court lawsuit pending resolution of the reexamination proceedings. On September 10, 2014, the U.S. Court of Appeals for the Federal Circuit affirmed the US Patent and Trademark Office's Patent Trial and Appeal Board's decision to reject all claims of the Patents. On June 1, 2015, the U.S. Supreme Court denied SPP's petition to review the Federal Circuit's decision. SPP has now exhausted all possibilities to seek review or reconsideration of the USPTO's rejections. It is expected that the USPTO will issue reexamination certificates canceling all claims of the Patents and the district court will dismiss all claims of alleged infringement of the Patents with prejudice. Biotage has also filed requests for reexamination of all patent claims in the US patent no 8,066,875 B2, which is a continuation of US patent no 7,381,327, and US patent no 8,070,957, which is a continuation of the US patent 7,410,571. All claims of the `875 and `957 patent are rejected, and SPP has appealed to the USPTO Patent Trial and Appeal Board. SPP asserted these patents in district court in a separate lawsuit, which is also stayed pending reexamination.

Biotage AB Approves Dividend

The board of directors of Biotage AB announced annual general meeting to be held on April 28, 2015, approved a dividend of SEK 0.75 per share, which in aggregate is a dividend in the amount of no higher than SEK 48,535, 835 and to carry forward SEK 428,680,080. Record date for dividend was resolved to be 30 April 2015.

Biotage AB Announces Group Earnings Results for the First Quarter Ended March 31, 2015

Biotage AB announced group earnings results for the first quarter ended March 31, 2015. Group net sales in the first quarter 2015 amounted to SEK 144.2 million compared to SEK 113.7 million, an increase by 26.8% compared to the corresponding quarter last year. At comparable exchange rates sales increased by 6.1%. Operating profit for the quarter amounted to SEK 18.0 million compared to SEK 9.5 million a year ago. Result after tax for the period amounted to SEK 18.6 million compared to SEK 8.1 million a year ago. Earnings per share amounted to SEK 0.29 compared to SEK 0.12 a year ago. The cash flow from operating activities amounted to SEK 23.8 million compared to SEK 10.8 million. Net cash at March 31 amounted to SEK 115.7 million, compared to SEK 95.0 million at December 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOT:SS kr18.70 SEK -0.30

BIOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $21.17 USD -0.70
International Stem Cell Corp $0.04 USD -0.005
Luminex Corp $17.81 USD +0.38
QIAGEN NV €24.98 EUR +0.56
Sequenom Inc $2.96 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOT Industry Range
Price/Earnings 20.2x
Price/Sales 2.4x
Price/Book 2.3x
Price/Cash Flow 20.2x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTAGE AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at